|
Experimental Biology 2007
(AAA, APS, ASBMB, ASIP, ASN,
ASPET)
Saturday April 28-Wednesday May
2, 2007
Washington, DC
Abstract
Deadline: November 8, 2006
ASPET Preliminary Program
ASPET Preliminary
Program
Symposia
P =
Pharmacogenomics Theme
D
=
Developmental Pharmacology Theme
● = A junior speaker
will be selected from the contributed abstracts to give a short talk
in this symposium
SUNDAY,
April 29
9:30 AM – 12:00 PM
Cannabinoids and Endocannabinoids I:
Pain and Obesity
Room: Convention
Center 143C
Chair: Aron H.
Lichtman
and Jenny L.
Wile
Overview.
Jenny L. Wiley,
Virginia Commonwealth University
Endocannabinoid modulation of pain and inflammation
Aron
H. Lichtman, Virginia Commonwealth University
Elucidating the role of the endocannabinoid system in
stress-induced analgesia
Andrea G. Hohmann,
University of Georgia
Development of selective FAAH and MGL inhibitors to treat
pain and psychiatric disorders
Daniele Piomelli,
University of California-Irvine
Development of
the CB1 receptor antagonist rimonabant for the treatment of
obesity-associated metabolic syndrome
Gêrard Le Fur,
Sanofi Aventis
●
Higher Order Organization of GPCR Signaling Components:
Lipid Rafts and Multimeric Protein Complexes
Room: Convention
Center 140B
Chair: Rennolds S.
Ostrom
Cyclic AMP
compartmentalization; insights from calcium-sensitive adenylyl
cyclases and key supporting players
Dermot M.F. Cooper,
University of Cambridge
Localization of GPCR
signaling components in caveolin-rich domains
Paul A. Insel, University of California, San Diego
Regulation of G protein signaling by cytoskeletal components
and membrane microdomains
Mark M. Rasenick,
University of Illinois at Chicago College of Medicine
GPCR interactions with PDZ scaffolds
Randy A. Hall,
Emory University School of Medicine
(Short Talk from Abstract) Reciprocal modulation of function
between the D1 and D2 dopamine receptors
and the Na+/K+-ATPase, a novel member of
the dopamine receptor signalplex.
Lisa A. Hazelwood, NINDS, NIH
(Short Talk from Abstract) Disruption of lipid rafts enhances
coupling of G-proteins to non-raft associated delta opioid
receptors in HEK293 cells.
Erica Sawyer Levitt, University of Michigan
P
Pharmacogenomics:
Frontiers to the Future
Room: Convention Center 143
A/B
Chairs: Rochelle M. Long
and Richard M. Weinshilboum
Cytochrome
P450 pharmacogenomics: Molecular mechanisms
Michel
Eichelbaum, Dr. Margarete Fischer-Bosch Institute of
Clinical Pharmacology, Stuttgart
Priorities and standards in pharmacogenetics research
David B. Goldstein, Duke University
The future of anti-hypertensive pharmacogenetics
Donna
K. Arnett, University of Alabama
Genetically-modified animal models for pharmacogenomics
research
Stephen B. Liggett, University of Maryland
Platforms for pharmacogenomics research and clinical
applications
Michael S. Phillips, McGill University
and Genome Quebec Innovation Center
●
D
Nicotine Modulates Adolescent Brain
Plasticity: Molecular, Neurochemical and Behavioral Changes
Room: Convention Center 142
Chairs: Shannon G. Matta, Burt
M. Sharp, and Frances M. Leslie
Gestational
nicotine exposure alters adolescent mesolimbic dopamine release
and nicotinic receptor expression
Burt M. Sharp,
University of Tennessee Health Science Center
Differential neuroadaptations to nicotine in adolescent and
adult rats
Sari Izenwasser, University of Miami
School of Medicine
Nicotine interaction with other drugs during sensitive
developmental periods
Frances M. Leslie, University of
California, Irvine
Gestational comorbid
exposure to nicotine and alcohol alters drug responsiveness in
offspring
Shannon G. Matta, University of Tennessee
Health Science Center
Sex specific effects
of gestational and adolescent exposure to tobacco smoke on
auditory and visual attention in adolescents
Leslie K. Jacobsen, Yale University School of Medicine
●
Technology Series: Nanotechnology in Disease & Therapeutics
Room: Convention Center 141
Chair: Shiladitya Sengupta
Nanoparticle assemblies as
quanitative molecular rulers and probes of conformational changes.
Bjoern M. Reinhard, Boston University
Ligand design for controlling assemblies of biomolecules.
Basar Bilgicer, Harvard University
BioMEMS and Bionanotechnology: Integrating life sciences and
engineering at the micro and nanoscale.
Rashid Bashir, Purdue University
Nanotechnology in drug
delivery systems.
Shiladitya Sengupta,
Harvard Medical School/Brigham and Women’s Hospital
(Short Talk from
Abstract) Riboflavin enhances cellular accumulation of
N-(2-hydroxypropyl) methacrylamide in breast cancer cells.
Lisa M. Bareford, University of Maryland
SUNDAY, April 29
3:00 –
5:30 PM
Cannabinoids and Endocannabinoids II:
Response to Pathogenic Processes
Room: Convention Center 143
C
Chairs: Ben A. Bahr and
Somnath Mukhopadhyay
Activation
of CB1 cannabinoid receptor: Structural studies
Alexandros
Makriyannis, Northeastern University
Behavioral and neurobiological significance of cannabinoid
action
Sam Deadwyler, Wake Forest University School
of Medicine
Endocannabinoid anandamide in neuroprotection and
angiogenesis: Interplay between CB1R and anandamide receptor.
Somnath
Mukhopadhyay, North Carolina Central University
The endocannabinoid system in neurodegenerative disorders:
Beneficial or noxious?
Vincenzo Di Marzo, Institute of
Biomedical Chemistry, Pozzuoli, Italy
Cellular and functional protection through dual modulation
of the endocannabinoid system
Ben A. Bahr, University
of Connecticut
Novel role of cannabinoid in the regulation of inflammation
Prakash Nagarkatti, University of South Carolina
School of Medicine
●
P
Genetic Regulation of GPCR/G-Protein/Adenylyl Cyclase Signaling:
Implication in Pathobiology and Therapeutics
Room: Convention Center 143
A/B
Chair: Ross D. Feldman
Genetic
variants of GPCRs linked to adenylyl cyclase activation
Paul A. Insel, University of California, San Diego
GRK genetic variants: Pathophysiological implications
Pedro A. Jose, Georgetown University
G-protein genetic variants
Wilfred Siffert, University of Essen
Adenylyl cyclase genetic
variants: Physiological and pathophysiological implications
Ross D. Feldman,
Robarts Research Institute, Canada
P
Pharmacogenomics 101: Incorporating the Current Issues into the
Curriculum
Room: Convention Center 208
A/B
Chair: Jack W. Strandhoy
Introduction
Jack W. Strandhoy, Wake Forest
University School of Medicine
Basic pharmacogenetics and molecular modeling
Russ B.
Altman, Stanford University School of Medicine
Therapeutic implications of pharmacogenomics: An overview
Alan R. Shuldiner, University of Maryland School of
Medicine
Ethical and legal implications of pharmacogenomics
Paul
R. Wolpe, University of Pennsylvania School of Medicine
Incorporating pharmacogenomics into the professional and
graduate curricula
Daniel A. Brazeau, State University of New York at Buffalo
● No
Time to Be “Bad To the Bone:” Osteoporosis and Bone Research in 2007
Room: Convention Center 142
Chairs: Henry U. Bryant
and Laura K. Nisenbaum
Current status of osteoporosis:
The disease, and outlook.
Kristine Harper, Eli Lilly and Company
Important
signal transduction pathways in the osteoblast.
Paula H. Stern, Northwestern University Medical School
Effect of PTH on
osteoblast differentiation.
Nicola C. Partridge, UMDNJ-Robert Wood Johnson Medical School
Stromal cell
differentiation and their role in the aging skeleton.
Pamela G. Robey, NIDCR, NIH
Toxicology of Nanomaterials
Room: Convention Center 141
Chairs: Nancy A.
Monteiro-Riviere
and Marc W. Fariss
Nanostructures and health - Nanochemistry perspectives.
Kevin D. Ausman, Oklahoma State University
Dermal toxicity of nanomaterials
Nancy A.
Monteiro-Riviere, North Carolina State University
Respiratory toxicity of
single-walled carbon nanotubes.
Anna A. Shvedova, NIOSH, Morgantown, WV
Peripheral microvascular effects of pulmonary exposure to
ultrafine particles.
Timothy R. Nurkiewicz, West Virginia University
Cardiovascular Gene Therapy
Room: Convention Center 140
B
Chair: Paul L. Hermonat
Cardiovascular gene therapy.
Joseph C. Glorioso, University of Pittsburgh School of Medicine
Gene
therapy against atherosclerosis.
Jawahar L. Mehta, University of Arkansas for Medical Science
Gene therapy for lung and cardiovascular disease.
Arthur L. Beaudet,
Baylor College of Medicine
Adenylyl cyclase gene transfer in heart failure.
H. Kirk Hammond,
UCSD
MONDAY,
April 30
9:30 AM – 12:00 PM
●
D
Child and Adolescent Depression: Why Do
Kids and Adults Respond Differently to Antidepressants?Room:
Convention Center 142
Chair: David B. Bylund
Introduction.
David B. Bylund, University of Nebraska Medical Center
Comparison of major
depressive disorder and its treatment in children and adults.
Christopher J. Kratochvil, University of Nebraska Medical Center
Behavioral neuropharmacology of adolescent brain development.
Linda P. Spear, SUNY-Binghamton
Psychotropic medications for children and adolescents.
Ronald T. Brown, Temple University
(Short Talk from Abstract) The forced-swim test and learned
helplessness paradigm in juvenile rats model the lack of
efficacy of tricyclic antidepressants in childhood and
adolescent depression.
A.L. Reed, University of Nebraska Medical Center
Animal models of juvenile
depression.
Kevin H. Happe, Creighton University School of Medicine
●
Post-Transcriptional Regulation of Gene Expression
Room: Convention Center 140
B
Chair: J. David Port
Post-transcriptional regulation of gene expression: A regulatory
paradigm for G-protein coupled receptors
J. David Port,
University of Colorado Health Sciences Center
Role of TTP in modulation of TNF alpha expression
Perry
J. Blackshear, NIEHS, NIH
Cell signaling-regulated
phosphorylation of RNA binding proteins controls the expression
of select labile transcripts
Roberto Gherzi,
National Institute for Cancer Research, Genoa, Italy
Post-transcriptional regulation of cyclin expression in breast
cancer
Rebecca S. Hartley, University of New Mexico
Health Science Center
P
Cardiovascular Pharmacogenomics: From Theory to Practice
Room: Convention Center 143
C
Chairs: Dan M. Roden
and Julie A Johnson
Genetics and
genomics of antiarrhythmic therapy
Dan M. Roden,
Vanderbilt University School of Medicine
Genetic and genomic markers of response to antihypertensive
therapy
Julie A. Johnson, University of Florida
Predicting drug response in hypercholesterolemia
Ronald
M. Krauss, Children’s Hospital Oakland Research Institute
Pre-prescription genotyping in heart failure: a concept
whose time is near?
Michael R. Bristow, University of
Colorado Health Science Center
Ray Fuller Symposium: Promise and
Pitfalls in the Search for New Drugs Targeted at Metabotropic
Glutamate Receptors
Room: Convention Center 143
A/B
Chair: Darryle D. Schoepp
mGluR5
negative allosteric modulators: in line for multiple clinical
proof of concept testing.
Vincent Mutel, Addex Pharmaceuticals, Plan Les Ouates, Switzerland
Roles of mGluRs in synaptic plasticity: implications for
therapeutic interventions.
Graham L. Collingridge, University of Bristol, United Kingdom
Allosteric potentiators of metabotropic glutamate receptors as a
novel approach for treatment of CNS disorders.
P. Jeffrey Conn, Vanderbilt University
mGlu receptors: Beyond the regulation of synaptic transmission.
Ferdinando Nicoletti, University of Catania, Italy
MONDAY,
April 30
3:00 – 5:30 PM
Early Clinical Development Strategies for
Monoclonal Antibody Experimental Agents in Non-Oncology Indications
Room: Convention
Center 141
Chair: Mary A. Mascelli
Anti
IL-12/23 monoclonal antibody for psoriasis: Biomarker validation
of mechanism-of-action and disease pathogenesis.
Kevin D. Cooper, Case Western Reserve University and University
Hospitals of Cleveland
Early development of drugs with new mechanisms of action.
Question-based rather than study-based development.
Adam F. Cohen, Center for Human Drug Research, Leiden, The
Netherlands
Immune response analysis for monoclonal antibodies in
development: Past experience and new expectations.
Carrie L. Wagner, Centocor, Inc., Malvern, PA
Regulatory considerations related to the design of early
clinical trials of monoclonal antibody experimental agents.
Libero Marzella, FDA
P
Recent Advances in our Understanding of the Flavin-containing
Monooxygenases: Role in Disease and Adverse Drug Reactions: In
Memory of Daniel Ziegler
Room: Convention Center 143 C
Chairs: Ronald N. Hines and
David E. Williams
Introduction/overview and dedication to Daniel M. Ziegler
Fred F. Kadlubar, NCTR, FDA
FMO1 and FMO3
developmental expression: Mechanisms
and variability
Ronald N. Hines, Medical College of
Wisconsin
FMO genetic polymorphisms and impact on function
Elizabeth A. Shephard, University College London
FMO and drug hypersensitivity
Craig K. Svensson, Purdue University of
College of Pharmacy, Nursing and Health Sciences
Summary and future direction of FMO research
David E.
Williams, Oregon State University
●
Imaging Localized cAMP Signaling Dynamics Organized by
AKAP Scaffold Proteins and Phosphodiesterases
Room: Convention Center 143
A/B
Chair: Mark L. Dell’Acqua
Cell signaling in
space and time
John D. Scott,
Oregon Health Sciences University
Coordination of neuronal cAMP
and calcium signaling by AKAP scaffolding
Mark L.
Dell’Acqua, University of Colorado at Denver Health
Sciences Ctr.
Local cAMP signaling regulation of T-cell activation
Kjetil Taskén, University of Oslo, Norway
Imaging local cAMP and PKA dynamics in cardiac myocytes
Manuela Zaccolo, University of Padua, Italy
(Short Talk from Abstract) Functional segregation of
prostaglandin- and isoproterenol-induced cAMP signals
Thomas C. Rich, University of South Alabama College of Medicine
TUESDAY,
May 1
9:30 AM – 12:00 PM
D
Molecular Mechanisms of Chemical Teratogenesis
Room: Convention Center 141
Chair: Peter G. Wells
Oxidative
DNA damage and repair in teratogenesis
Peter G. Wells,
University of Toronto, Canada
Oxidative stress and signal transduction in teratogenesis
Jason Hansen, Emory University School of Medicine
Oxidative stress in diabetic teratogenesis
Mary R. Loeken,
Harvard University
Neonatal apoptotic mechanisms of neurodevelopmental deficits
John W. Olney, Washington University School of Medicine
●
Regulation of Drug Metabolizing Enzymes and Transporters in
Inflammatory Disease States:
A Symposium in Honor of the Career of Dr. Kenneth W. Renton
Room: Convention Center
140 B
Chair: Edward T. Morgan
Overview and
tribute to the contributions of Dr. Kenneth W. Renton
Edward T. Morgan, Emory University
Inflammation and infection: Hazards for drug safety
Kenneth
W. Renton, Dalhousie University, Halifax, Canada
Regulation of cytochrome P450 and UGT enzymes in live and
sterile models of infection
Edward T. Morgan, Emory
University
Regulation of drug transporters in inflammation
Micheline
Piquette-Miller, University of Toronto, Canada
Repression of CYP3A4 by inflammation associated with cancer
Graham Robertson, University of Sydney, Australia
Regulation of CYP3A metabolism and P-glycoprotein-mediated drug
transport during CNS inflammation
Kerry B. Goralski,
Dalhousie University, Halifax,Canada
●
P
Impact of Pharmacogenomics on the Treatment of Neuropsychiatric
Disorders: From Drug Target to Targeted Therapy
Room: Convention Center 143 A/B
Chair: Laura K. Nisenbaum
Genetic variants associated with
neuropsyciatric disease susceptibility.
David Goldman, NIAAA, NIH
Current applications of
pharmacogenetic testing in antidepressants and antipsychotic
treatment: Focusing on CYP2D6 and CY2C19
Jose de Leon, University of Kentucky
Genetic variation and
response to antidepressants
Roy H. Perlis,
Harvard Medical School/Massachusetts General Hospital
From genome scan to functional biology for antipsychotic-induced
weight gain
Laura K. Nisenbaum, Eli Lilly and Company
TUESDAY,
May 1
3:00 – 5:30 PM
●
Multiple Calcium Channels in the Vasculature: Regulation of
Arterial Tone
Room: Convention Center 143
A/B
Chair: Joseph E. Brayden
Store-operated channels and
vascular tone.
Victoria M. Bolotina, Boston University School of Medicine
Receptor- and stretch-induced activation of calcium entry
channels.
Donald L. Gill, University of Maryland School of Medicine
Calcium sparklets in arterial smooth muscle.
Luis F. Santana, University of Washington
School of Medicine
Mechanisms of Ca2+ regulation mediated by TRP
channels in vascular smooth muscle.
Joseph E. Brayden, University of
Vermont
College of
Medicine
P
Mouse Meets Man: Advanced Murine Models for Use in Cancer Drug
Development
Room: Convention Center 141
Chairs:
Thomas C. Stover and David Tuveson
Genetically
engineered mouse models of pancreatic exocrine cancer
David A. Tuveson,
Cambridge Research Institute/CRUK,
Cambridge U.K.
Pathway-specific
biomarkers in mouse models of prostate cancer
Charles L. Sawyers,
Memorial Sloan Kettering Cancer Center
Modeling the role of BRCA1, BRCA2, and Trp53 loss-of-function in
breast cancer
Jos Jonkers, Netherlands Cancer Institute
Mutant EGFR-dependent
lung cancer: Lessons from mouse models
Katerina A. Politi, Memorial Sloan
Kettering Cancer Center
WEDNESDAY, May 2
8:30 – 11:00 AM
●
D
Perinatal Stress Alters Drug Responses into
Adulthood
Room: Convention Center 140
B
Chair: Mike J. Kuhar
Maternal
separation as a perinatal stressor.
Darlene Francis, University of California, Berkeley
Maternal separation
affects propensity to abuse drugs.
Mike J. Kuhar, Emory University
Effects of maternal
separation on brain serotonin systems.
Aleksandra Vicentic, NIMH, NIH
Neonatal isolation as a model of stress and its effects on
drugs in adulthood.
Therese A. Kosten,
Baylor
College of Medicine
Epigenetic mechanisms as candidates for long term changes in
drug effects.
Moshe Szyf, McGill University
●
Nitric Oxide Deficiency and Cardiovascular Disease
Room: Convention Center 143
A/B
Chair: Alex F.Y. Chen
Nitric oxide deficiency and
cardiovascular disease: Lessons from NO synthase knockout and
transgenic studies.
Marielle Scherrer-Crosbie, Massachusetts General Hospital
Polymorphisms in the eNOS gene and the risk of ischemic heart
disease.
Dennis McNamara, University of Pittsburgh Medical Center
GTP Cyclohydrolase I and eNOS uncoupling in salt-sensitive
hypertension.
Alex F. Chen, Michigan State University
Endothelial dysfunction and nitric oxide enhancing theraphy:
A new approach to the treatment of heart failure.
Anne L. Taylor, University of Minnesota Medical School
(Short Talk from
Abstract) Vascular endothelial growth factor 121 attenuates
hypertension, myocardial necrosis and renal injure-induced by Nω
–nitro-L-arginine methyl ester and angiotensin II in rats.
Ying Zhang, Amgen
●
P
Genetic Variations in Regulatory Factors Affecting Drug
Metabolism/Disposition
Room: Convention Center 143
C
Chair: Erin Schuetz
PPARG (peroxisome
proliferator activated receptor gamma) variation may underlie
response to TZD (troglitazone) therapy in women at risk for type
2 diabetes.
Richard M. Watanabe, University of Southern California
Pharmacogenetics of constitutive androstane receptor (CAR).
Jatinder K. Lamba, St. Jude Children’s Research Hospital
(Short Talk from
Abstract) CAR2 displays unique ligand binding and RXRα
heterodimerization characteristics.
Joshua G. Dekeyser, Penn State
FXR: Interindividual polymorphisms and variation in FXR
expression.
Richard B. Kim, University of Western Ontario
PXR: Genetic
variants of PXR (NR1I2)
and their implications in
drug metabolism and pharmacogenetics
Erin Schuetz,
St. Jude Children’s Research Hospital
●
Pharmacology and Signal Transduction of Taste
Room: Convention Center 141
Chair: R. Kyle Palmer
Coding of
taste signaling from receptor to brain.
Robert F. Margolskee, Mount Sinai School of Medicine
Behavioral assessment of taste function in rodent models
Alan C. Spector, University of Florida
Transient receptor potential (TRP) channels in taste signaling.
Robert W. Bryant, Linguagen Corporation
Effects of therapeutic drugs on taste and their impact on
compliance and nutritional status.
Susan S. Schiffman, Duke University Medical Center
Mechanisms of Idiosyncratic Drug Reactions
Room: Convention Center 142
Chairs: Cynthia Ju and
Dennis R. Petersen
Cellular consequences of drug bioactivation.
B. Kevin Park, University of Liverpool
Role of cytokines and other factors in determining
susceptibility to drug-induced liver injury.
Lance R. Pohl, NHLBI, NIH
Animal
models of idiosyncratic drug reactions.
Jack Uetrecht, University of Toronto Faculty of Pharmacy and
Medicine
Vaccine-induced cellular immunity: Integrating innate and
adaptive signaling pathways
Ross M. Kedl, National Jewish medical and Research Center, Denver
How do systemically administered drugs provoke reactions in the
skin?
Craig K. Svensson, Purdue University College of Pharmacy, Nursing and Health
Sciences
Division
Sessions
SUNDAY, April 29
9:30 AM –
12:00 PM
Division for Pharmacology Education Symposium:
Pharmacological Characterization of Modified Genotypes: The
Fundamentals
Room: Convention Center 156
Chair: William B. Jeffries
Introduction.
William B. Jeffries, Creighton University
Measurement of behavior modifications in genetically altered
animals.
Sam J. Enna, University of Kansas Medical Center
Assessing cardiovascular phenotypes in the whole animal.
Joseph R. Haywood, Michigan State University
Measurement of drug metabolism and pharmacokinetics in
genetically modified mice.
Denis M. Grant, University of Toronto
The use of transgenic animals in
drug discovery.
Bryan F. Cox, Abbott Laboratories
MONDAY,
April 30
9:30 AM –
12:00 PM
Division for Drug Discovery, Development,
and Regulatory Affairs Symposium: Assessing Abuse Liability for
Drug Discovery and Development: A Changing Environment
Room: Convention Center 141
Chair: Richard H. Alper
Cellular
and molecular mechanisms contributing to substance abuse and
neurotoxicity
Annette E. Fleckenstein,
University of Utah
The translation and application of rodent models for abuse
liability testing
Andy Mead, Pfizer, Ltd.,
Sandwich, U.K.
Clinical abuse liability assessments
Edward M.
Sellers, Ventana
Clinical Research Corporation, Toronto
Regulatory environment in
abuse liability assessments
Douglas Throckmorton, FDA
3:00 –
5:30 PM
Division for Behavioral Pharmacology
Symposium: Its all the Rave: Behavioral, Neuropharmacological
and Toxic Effects of MDMA and Methamphetamine
Room: Convention Center 140 B
Chairs: Michael A. Nader and
Matthew L. Banks
Tolerance to
the reinforcing and subjective effects of MDMA in humans.
Andrew C. Parrott, University of Wales, Swansea
MDMA- and MA-induced brain changes: Imaging studies in nonhuman
primates and humans.
Una D. McCann, Johns Hopkins University School of Medicine
Ambient temperature interactions related to MDMA abuse; MDMA
abuse and neurotoxicity as measured by PET.
Matthew L. Banks, Wake Forest University School of Medicine
Neurochemical alterations and long-term consequences of MA and
MDMA abuse.
Annette E. Fleckenstein, University of Utah
The role of serotonin receptors in the behavioral pharmacology
of MDMA.
Kathryn A. Cunningham, University of Texas Medical Branch,
Galveston
Division for Cardiovascular Pharmacology
Programming: Junior Scientists
Competition
Room: Convention Center 208
A/B
Chairs: Emel Songu-Mize,
Alyson Miller and Kristina Fetalvero
Graduate
Student Presentations
Diminished MnSOD contributes to
endothelial progenitor cell dysfunction, impaired angiogenesis
and wound healing in
type 2 diabetes.
Eric J. Marrotte, Michigan State University (Advisor: Alex
Chen)
Molecular characterization of the 8-iso-PGF2α
alpha interaction with the thromboxane A2 receptor and its
signaling mechanisms in
human platelets.
Fadi T. Khasawneh, University of Illinois at Chicago (Advisor:
Guy Le Breton)
Rosuvastatin provides pleiotropic protection against pulmonary
hypertension, right ventricular hypertrophy and coronary
endothelial dysfunction in rats.
Xiaowei Sun, University of Alabama at Birmingham (Advisor:
David D. Ku)
Postdoctoral
Scientist Presentations:
ADP stimulates human endothelial
cell migration via P2Y1 receptor-mediated MAPK pathways.
Jianzhong Shen, Cleveland Clinic Foundation (Mentor: Paul E.
DiCorleto)
Caveolin-1 potentiates Src and Akt signaling in isoflurane-induced
cardiac protection.
Yasuo M. Tsutsumi, UCSD (Mentor: David M. Roth)
Graduate Student
runners-up posters:
Ethanol preconditioning is
dependent on the activation of 5'-AMP-activated protein kinase.
F. Spencer Gaskin, University of Missouri (Advisor: Ronald J.
Korthuis)
Overexpression of the inward rectifier K+ current
(IK1) accelerates and stabilizes rotors.
Sami F. Noujaim, SUNY Upstate Medical University (Advisor:
Jose Jalife)
Chemical genetic analysis of glycome regulation of
vasculogenesis.
Stephanie M. Piecewicz, Harvard/MIT (Advisor: Shiladitya
Sengupta)
Estrogen decreases mitochondrial ROS production in human brain
endothelial cells.
Ali Razmara, UCI (Advisor: Sue P. Duckles)
Postdoctoral
Scientist runner-up poster:
Basal and ACh-stimulated
intracellular Ca2+ signals in intact endothelium
originate from IP3-sensitive stores.
Jonathan
Ledoux, University of Vermont (Mentor: Mark T. Nelson)
Division for Cardiovascular Pharmacology
Benedict R. Lucchesi Distinguished Lecture and Junior Scientists
Competition
Room: Convention Center 208
A/B
Chairs: David D. Ku and William
M. Armstead
Lecturer:
Garrett Gross, Medical College of
Wisconsin
A Novel Cardioprotective Paradigm: The CYP450 Pathway of
Arachidonic
Acid Metabolism.
P
Division for Toxicology Symposium: Toxicogenomics
Approaches for Evaluating Drug and Chemical Toxicity
Room: Convention Center
142
Chair: Curt J. Omiecinski
Gene expression profiling in
primary human hepatocytes as predictors of interindividual
variability in chemical response.
Curt J. Omiecinski, Penn State University
Application of toxicogenomics towards idiosyncratic
hepatotoxicity.
Jeffrey F. Waring, Abbott Laboratories
The Comparative Toxicogenomics Database: Promoting understanding
about the mechanisms of chemical actions.
Carolyn Mattingly, Mount Desert Island Biological Laboratory,
Salisbury Cove, ME
Genetic and genomic approaches to predicting chemical toxicity.
Christopher A. Bradfield, University of Wisconsin
Data analytic
platforms and methods for mining proteome data and its
integration with genomic information.
Martin W. McIntosh, Fred Hutchinson Cancer Research Ctr, Seattle
TUESDAY, May 1
9:30 AM
– 12:00 PM
P
Division for Clinical Pharmacology,
Pharmacogenetics, and Translational Medicine Symposium: The
Regulatory Approach to Pharmacogenomics: An International
Perspective
Room: Convention Center
142
Chairs: Lawrence J. Lesko and Felix W. Frueh
U.S. FDA
regulatory approaches to pharmacogenomics.
Felix W. Frueh, FDA
Pharmacogenomics: A global view from a global company.
Celia Brazell, GlaxoSmithKline,
Middlesex, U.K.
A framework for pipeline
efficacy pharmacogenetics.
Allen D. Roses, GlaxoSmithKline, Inc., Research Triangle Park
Development of devices for pharmacogenomic testing.
Janet A. Warrington, Affymetrix
Drug-test co-development: A real-life perspective.
Jeffrey R. Gulcher, deCODE Genetics
Panel discussion. From
science to regulation to medical practice: The challenge of
implementation.
Larry J. Lesko, FDA and Wayne A. Rosenkrans, AstraZeneca
and Personalized Medicine Coalition
2:00
– 3:00 PM
Division for Drug Metabolism Early Career
Achievement Award Lecture
Room: Convention
Center 143 C
Chairs: Larry S. Kaminsky
and Kenneth E. Thummel
Lecturer: Qing Ma,
NIOSH, CDC
Xenobiotic-activated receptors: From transcription, to drug
metabolism, to disease
3:00 –
5:30 PM
Drug Metabolism Division Platform Session:
Biotransformation and Drug Transport
Room: Convention Center 143 C
Chairs: Larry S. Kaminsky and
Kenneth E. Thummel
Division for Molecular Pharmacology
Postdoctoral Award Finalists
Room: Hyatt Hotel
Constitution C Ballroom
Chair: Stephen M. Lanier
Along the continuum of G-protein
signaling with additional thoughts on CQ and PQ relative to the
art of science.
S.M. Lanier. Medical
University of South Carolina
Postdoctoral Scientist Award
Finalists:
The retinoic acid
receptor-related orphan receptor (ROR) regulates human CYP2C8.
Y. Chen.
NIEHS, NIH, Research Triangle Park, NC. (Advisor: J.A.
Goldstein)
Cellular models of altered base excision repair
reveal a differential contribution of reactive oxygen
species-induced 7,8-dihydro-8-oxo-2’-deoxyguanosine to the
cytotoxic mechanisms of platinum anticancer drugs cisplatin and
oxaliplatin.
T.J. Preston. University of Toronto
Faculty of Pharmacy (Advisor: P.G. Wells)
Impaired c-src kinase regulation of muscle
contraction during colonic inflammation is due to nitrosylation
of Ca 2+channels.
G.R Ross.
Virginia
Commonwealth University (Advisor: H. Akbarali)
Function of caveolin-1 in paclitaxel-mediated
cytotoxicity in breast cancer.
A.N.
Shajahan.
Georgetown University (Advisor: R. Clarke)
Vasoactive intestinal peptide transactivates the
androgen receptor through a PKA-dependent extracellular
signal-regulated kinase pathway in prostate cancer cells.
Y. Xie.
Creighton University (Advisor: Y. Tu)
Division for Neuropharmacology Postdoctoral
Scientist Award Finalists
Room: Convention Center 140
B
Chair: Susan G. Amara
Neurotransmitter transporters: A dance of domains and
substrates.
Susan G. Amara, University of Pittsburgh School of Medicine
Reciprocal modulation of function
between the D1 and D2 dopamine receptors and the Na+/K+-ATPase,
a novel member of the dopamine receptor signalplex.
Lisa A. Hazelwood, NINDS, NIH
Enhancement of endogenous cannabinoid responses through FAAH
inhibition provides cellular and functional protection against
excitotoxic brain damage.
David A. Karanian, University of Connecticut
Distinct roles of spinal muscarinic receptor subtypes in control
of glycinergic input revealed by muscarinic receptor knockout
mice.
Hong-Mei Zhang, University of Texas, Houston
Alteration in acetylcholinesterase glycosylation of rat brain in
memory disorder.
Amitava Das, Mayo Clinic College of Medicine
Impaired HPA axis and their feedback regulation in SERT knockout
mice.
Xue Jiang, University of Texas Medical Branch, Galveston
Division for Systems and Integrative
Pharmacology Symposium: Regenerative Pharmacology: Integrative Pharmacology of Engineered
Tissues
Room: Convention Center 142
Chair: George J. Christ
Regenerative
pharmacology: An overview.
George J. Christ, Wake Forest University
Mechanical and matrix effects on cell phenotype in engineered
cardiovascular tissues.
Jan P. Stegemann, Rensselaer Polytechnic Institute, Troy, NY
Challenges and opportunities in engineering clinically relevant
bladder implants: The importance of pharmacology and phenotype.
Tim Bertram, Tengion,
Inc,
Winston-Salem
Pharmacology of
engineered and regenerating tissues.
Karl-Erik Andersson, Wake Forest University
Cyclic GMP and vascular smooth muscle cell phenotype.
Thomas Lincoln, University of South Alabama College of Medicine
Special Sessions
SATURDAY, April 28
12:30 - 3:00 pm
2007 Teaching Institute:
Integrated Strategies in Pharmacology Education: Simulation, Case-
& Team-Based Approaches
Room: Convention Center
142
Chairs: Lynn M. Crespo and Jordan E. Warnick
Overview: Multiple approaches to
the teaching of pharmacology.
Lynn M. Crespo, University of South Florida and Jordan E.
Warnick, University of Maryland School of Medicine
Lecture-based spproach to pulmonary pharmacology.
Jordan E. Warnick, University of Maryland School of Medicine
Case-based approaches
in pulmonary disease.
Lynn M. Crespo, University of South Florida
Simulators in acute asthma case (albuterol and steroids).
John L. Szarek, Ross University School of Medicine
Team-based approach to pulmonary pharmacology.
Robert J. Theobald, A.T. Still University
1:00 - 3:15 pm
Workshop: Mentoring: How to Find a Good
Mentor and How to Be a Good Mentor
Room: Convention Center 143
C
Chairs: Martha I.
Dávila-Garcia and Gonzalo E. Torres
How to find
a good mentor.
Howard G. Adams, H.G. Adams
and Associates, Inc.
How to be a good mentor.
James G. Townsel, Meharry Medical College
3:15 - 5:30 pm
Graduate Student-Postdoctoral Colloquium:
Pharma Phair
Room: Convention Center 143
A/B
Chairs: Stephanie W. Watts
and Walter C. Prozialeck
Trainees will first hear, then
interact with professionals from different career paths to view the
wide variety of options open to them after their formal training.
Academicians:
Biotech:
Consultant:
Legal:
NIH:
Pharmaceutical Industry:
Pharmacy:
Public Affairs:
Science Writer:
Scientific Officer:
Teacher: |
|
Barbara S. Beckman, Tulane University School of Medicine
Michael Babich,
ImmvaRx
Marie T. Rock,
Chirality, LLC
Blair E. Taylor,
Venable LLP
Lance R. Pohl,
NIH, NHLBI
Ryan M. Fryer,
Abbott Laboratories
Timothy J.
Maher, Massachusetts College of Pharmacy
James S.
Bernstein, ASPET
Jill U. Adams,
Albany, NY
Christine K. Carrico, ASPET
Walter C.
Prozialeck, Midwestern University |
6:00 -
9:00 pm
ASPET Business Meeting and Awards Reception
Room: Convention Center
Ballroom A
MONDAY, April 30
8:00 - 10:00 am
ASPET/APS Women’s Committees Workshop:
Being Heard: The Microinequities that Tilt the Playing Field
Room: Convention Center
201
Chairs: Susan F. Steinberg, Holly H. Brevig and Kathleen
H. Berecek
Overview: Women in academic science
and engineering - Beyond bias and barriers.
Joan A. Steitz,Yale University
Leveling the playing
field: A focus on students
Barbara A. Horwitz, University
of California, Davis
Institutional strategies to improve the status of women.
Jeanine D'Armiento, Columbia University, College of Physicians and Surgeons
Succeeding in a
male-dominated environment.
Florence P. Haseltine, NICHD, NIH
Breakout Sessions
12:45 - 1:45 pm
EB 2007 Public Policy Session: NIH at the Crossroads: How
Diminished Funds Will Impact Biomedical Research and What Scientists
Can Do About It
Room: Convention Center
Ballroom C
Chair: Leo T. Furcht
Speakers:
Elias Zerhouni, Director, NIH
The Honorable John E. Porter, Hogan & Hartson,
and former Chair of the U.S. House of
Representatives Labor/HHS Appropriations Subcommittee
Lectures
SUNDAY, April 29
8:15 - 9:15 am
Julius Axelrod Award Lecture
Room: Convention Center 143
A/B
Lecturer:
Tong H. Joh., Cornell
University Weill Medical College
Phox and Nox and ROS
in a box of dopaminergic neurodegeneration: Roles of MMP-3.
1:30 - 2:30 pm
Torald Sollmann Award Lecture
Room: Convention Center 143
A/B
Lecturer: Sue P. Duckles.,
University of California, Irvine
A career in
pharmacology: In search of beauty and joy.
MONDAY, April
30
8:15 - 9:15 am
Ray Fuller Lecture in the Neurosciences
Room: Convention Center 143
A/B
Lecturer: Darryle D. Schoepp,
Lilly
Research Labs
Case Study from Bench to Bedside: Modulators of mGlu2 and mGlu3
Receptors to Treat Psychiatric Disorders
Satellite Meetings
FRIDAY & SATURDAY, April
27-28
3RD GPCR Colloquium
Room: Convention Center 204
A/B/C
(Separate, Advance Registration
Required)
Chairs: Kim A Neve and
Olivier Civelli
Behavioral Pharmacology Society Meeting
Room: Convention Center 201
(Separate, Advance Registration
Required)
Contact Galen R. Wenger:
grwenger@uams.edu or 501-686-8040
Public
Affairs Sessions
EB
2007 Public Affairs Session
Room: Convention Center
Ballroom C
NIH at the Crossroads: How Diminished Funds Will
Impact Biomedical Research
And What Scientists Can Do About It
Capitol Hill Visits
APS Public Affairs Sessions
ASBMB Public Affairs Session
Howard K. Schachman Public Service
Award Lecture
General Information
Awards
Call for Abstracts
Hotels
Registration
|
